Ghant V K, Hiramoto N S, Gillespie G Y, Gauthier D K, Hiramoto R N
Department of Microbiology, Comprehensive Cancer Center, University of Alahama at Birmingham, 35294-0007, USA.
J Neurooncol. 2000 Mar;47(1):1-10. doi: 10.1023/a:1006475516746.
Mouse YC8 T cell lymphoma was used as a model to determine whether an effective immunotherapy procedure could be devised for the treatment of lymphoma localized to the brain. Implantation of 5 x 10(4) YC8 cells into the left cerebral hemisphere induced rapid loss of the animal's body weight. Severe loss of weight and early deaths were observed in the untreated control group. Although resistance can be conferred to the brain by immunization of naive BALB/c mice, adoptive chemoimmunotherapy procedures were surprisingly not effective in inducing remissions in animals with lymphoma confined to the brain. Even passive transfer of effector cells from immunized, tumor resistant donor animals combined with systemic IL-2 treatment did not impart resistance to recipients with brain tumors. However, regression of the intracranial tumor and apparent cures could be accomplished, when ex vivo cultured effector cells were transferred intravenously.
小鼠YC8 T细胞淋巴瘤被用作模型,以确定是否可以设计出一种有效的免疫疗法来治疗局限于脑部的淋巴瘤。将5×10⁴个YC8细胞植入左脑半球会导致动物体重迅速下降。在未治疗的对照组中观察到严重体重减轻和早期死亡。尽管通过对未接触过抗原的BALB/c小鼠进行免疫可使其对脑部产生抵抗力,但过继性化学免疫疗法在诱导局限于脑部的淋巴瘤动物缓解方面出人意料地无效。即使将来自免疫的、具有肿瘤抵抗力的供体动物的效应细胞进行被动转移并结合全身性白细胞介素-2治疗,也不能使患有脑肿瘤的受体产生抵抗力。然而,当将体外培养的效应细胞静脉内转移时,颅内肿瘤可以消退并实现明显治愈。